GlaxoSmithKline is making ambitious plans to expand its R&D operations in China. According to Glaxo's Carol Zhu, who runs the operation, the company will more than double the number of researchers it has on staff in China. The R&D arm will grow from a staff of 170 today to 200 by year's end and plans to reach 350 next year. The pharma giant then plans to hold staffing at that level for several years before adding new researchers.

- read the report [1] from Healthcare Digital

Related Articles:
GSK blueprints $100M Chinese R&D center [2]
GSK shakes up R&D [3]
R&D spending going gangbusters in China [4]